ERBB2 and breast cancer: In patients with HER2+ BC, the confirmed ORR was 42.9% (95% CI, 17.1–71.1), mPFS was 11.0 months (95% CI, 4.4–16.4), mOS was 19.5 months (95% CI, 12.2- NE).